NCT06757894View on ClinicalTrials.gov

Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

February 1, 2028

Study Completion Date

February 1, 2034

Conditions
Follicular Lymphoma (FL)
Interventions
DRUG

Zuberitamab

375 mg/m², administered on Day 1 (D1) of Cycles 1-6 (C1-C6)

DRUG

Bendamustine

90 mg/m², administered on D1-2 of C1-C6

Trial Locations (1)

510060

Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou

All Listed Sponsors
collaborator

Gansu Cancer Hospital

OTHER

collaborator

Ganzhou Cancer Hospital

UNKNOWN

collaborator

Fifth Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Fifth Affiliated Hospital of Guangzhou Medical University

OTHER

lead

Sun Yat-sen University

OTHER